Erratum: Mn-porphyrins as novel molecular Mri contrast agents (Journal of Endourology (2011) DOI: 10.1089/end.2012.0171);Mn porphyrins as novel molecular magnetic resonance imaging contrast agents

Journal of Endourology

Volumn 26, Issue 11, 2012, Pages 1420-1424

  Mouraviev, Vladimir ^a,b   Venkatraman, Talaignair N ^a   Tovmasyan, Artak ^a   Kimura, Masaki ^a   Tsivian, Matvey ^a   Mouravieva, Vladimira ^a   Polascik, Tom J ^a   Wang, Haichen ^a   Amrhein, Timothy J ^a   Batinic Haberle, Ines ^a   Lascola, Christopher ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIDOL; MANGANESE MESO TETRAKIS(N ETHYLPYRIDINIUM 2 YL)PORPHYRIN; MANGANESE MESO TETRAKIS(N HEXYLPYRIDINIUM 2 YL)PORPHYRIN; METALLOPORPHYRIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG BINDING; DRUG STRUCTURE; IMAGE QUALITY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

EID: 84869049825     PISSN: 08927790     EISSN: 1557900X     Source Type: Journal    
DOI: 10.1089/end.2011.0133.ret     Document Type: Erratum

References (18)

1. Engelbrecht MR, Puech P, Colin P, et al. Multimodality magnetic resonance imaging of prostate cancer. J Endourol 2010;24:677-684
2. Aigner F, Mitterberger M, Rehder P, et al. Status of transrectal ultrasound imaging of the prostate. J Endourol 2010;24:685-691
3. Batinic-Haberle I, Rajic Z, Tovmasyan A, et al. Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. Free Radic Biol Med 2011;51:1035-1053
4. Miriyala S, Spasojevic I, Tovmasyan A, et al. Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta 2012;1822:794-814
5. Batinic-Haberle I, Rebouças JS, Spasojevic I. Superoxide dismutase mimics: Chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal 2010;13:877-918
6. Spasojevic I, Li AM, Tovmasyan A, et al. Accumulation of porphyrin-based SOD mimics in mitochondria is proportional to their lipophilicity. Free Radic Biol Med 2010: S199
7. Sheng H, Spasojevic I, Tse HM, et al. Neuroprotective efficacy from a lipophilic redox-modulating Mn(III) NHexylpyridylporphyrin, MnTnHex-2-PyP: Rodent models of ischemic stroke and subarachnoid hemorrhage. J Pharmacol Exp Ther 2011;338:906-916
8. Bueschen AJ, Lockhart ME. Evolution of urological imaging. Int J Urol 2011;18:102-112
9. Sciarra A, Panebianco V, Ciccariello M, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010; 16:1875-1883
10. Verma S, Rajesh A. A clinically relevant approach to imaging prostate cancer: Review. AJR Am J Roentgenol 2011; 196(suppl 3):S1-S10
11. Martin DR. Nephrogenic systemic fibrosis and gadoliniumenhanced magnetic resonance imaging: Does a US Food and Drug Administration alert influence practice patterns in CKD? Am J Kidney Dis 2010;56:427-430
12. Rees O, Agarwal SK. Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media. Clin Radiol 2010;65:636-641
13. Gauden AJ, Phal PM, Drummond KJ. MRI safety: Nephrogenic systemic fibrosis and other risks. J Clin Neurosci 2010;17:1097-1104
14. Batinić-Haberle I, Spasojević I, Stevens RD, et al. Manganese (III) meso-tetrakis(ortho-N-alkylpyridyl)porphyrins. Synthesis, characterization, and catalysis of O2 c - dismutation. J Chem Soc, Dalton Trans 2002:2689-2696
15. Rabbani ZN, Spasojevic I, Zhang X, et al. Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium- 2-yl)porphyrin, MnTE-2-PyP(5 +), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med 2009;47:992-1004
16. Ye X, Fels D, Tovmasyan A, et al. Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res 2011;45:1289-1306
17. Spasojevic I, Kos I, Benov LT, et al. Bioavailability of metalloporphyrin-based SOD mimics is greatly influenced by a single charge residing on a Mn site. Free Radic Res 2011;45:188-200
18. Rajic Z, Tovmasyan A, Spasojevic I, et al. A new SOD mimic, Mn(III) ortho N-butoxyethylpyridylporphyrin, combines superb potency and lipophilicity with low toxicity. Free Radic Biol Med 2012;52:1828-1834